Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06806371

PREDICTORS of CARDIOVASCULAR OUTCOMES in INDIVIDUALS with DIFFERENT OBESITY PHENOTYPES

The aim of this observational study is to identify and evaluate adverse cardiovascular outcomes in metabolically healthy obese individuals in a cohort of 25 to 64 years of age, both men and women. The main questions it aims to answer are: what are the markers of adverse cardiovascular outcomes in metabolically healthy obese individuals?

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

25 year–64 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ryazan State Medical University

Ryazan, 390026, Russia

About this study

The study is planned to include 1,600 people of the Ryazan city population aged 25-64 years, selected using a three-stage cluster sampling method. Participation in the study is voluntary, as evidenced by the signing of informed consent. Among them, it is planned to select obese people and conduct phenotyping according to the criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III).

It is planned to conduct a survey at all stages of the study. The questionnaire will include the following modules: social status, dietary habits (dietary habits), physical activity, smoking, alcohol consumption, family history, personal history, objective data, laboratory data, data on medical care and disability, quality of life questionnaire. Measurement of blood pressure, heart rate, height, weight, waist circumference. Laboratory tests: total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, fibrinogen, uric acid, C-reactive protein (by quantitative method).

Next, it is planned to monitor the examined individuals and collect endpoints for 36 months. The endpoints are: death from any cause, stroke of any etiology, fatal and non-fatal myocardial infarction and coronary artery revascularization, carotid artery surgery. Next, it is planned to establish a relationship between the studied indicators and the frequency of adverse outcomes in individuals with different obesity phenotypes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inc1. Body mass index >=30 kg/m2 . 2. Less than three of the five criteria according to The National Cholesterol Education Program's Adult Treatment Panel III, NCEP/ATP III):

  • Systolic blood pressure >130 and/or diastolic blood pressure >85 mmHg,
  • Triglycerides >1.7 mmol/L,
  • High density lipoproteins < 1.03 (men), < 1.29 (women);
  • fasting plasma glucose >=5.6 mmol/L,
  • waist circumference >102 cm (men), >88 cm (women)lusion Criteria:

Exclusion criteria

The presence of

  • signs of chronic heart failure,
  • coronary heart disease,
  • infiltrative or hypertrophic obstructive cardiomyopathy or constrictive pericarditis,
  • heart disease or valve disease, which can be expected to lead to surgery during the study,
  • cancer.

Treatment and study plan

Primary outcomes

  1. Number of participants with adverse cardiovascular outcomes

    Time frame: From inclusion in the study to three years

    The number of people with the following adverse outcomes will be recorded: death from any cause, nonfatal myocardial infarction, nonfatal stroke, coronary artery revascularization, carotid artery surgery

Sponsors and collaborators

Lead sponsor

Ryazan State Medical University

Other

Registry information

Acronym: PRE-CAR

Important dates

Study start
2023
Primary completion
2027
Study completion
2028
First posted
Feb 4, 2025
Registry last updated
Feb 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.